Preparation method of giant liposome without surfactant
Through microfluidic technology without surfactant, the self-assembly method of phospholipids and squalene is used to prepare giant liposomes, which solves the problems of uneven size and low packaging efficiency in the existing methods, and achieves biocompatibility and Stability, suitable for artificial cells and biological fields.
Patent Information
- Application Number
- CN202411144520.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
Smart Images

Figure CN119015992A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to a method for preparing giant liposomes without surfactant, and belongs to the technical field of microcapsule or microsphere manufacturing in colloid chemistry. Background Art
[0002] Liposomes are a type of molecular ordered assembly with a closed bilayer structure that is self-assembled from phospholipid molecules. They are also called phospholipid vesicles, which have a water core surrounded by one or more phospholipid bilayers or lamellae. Liposomes can be classified according to their size (small, large and giant liposomes), the number of phospholipid layers (monolayer, oligolayer and multilayer) and the charge of phospholipids (neutral, anionic or cationic). Giant liposomes (GUVs) are liposomes with a particle size greater than 1μm, ultra-high encapsulation volume and encapsulation rate, and a size close to that of most biological cells. They are widely used as artificial cell models, drug carriers and reaction primitives. Therefore, GUVs have potential application value in many fields such as analytical testing, biomedicine, chemistry, and materials.
[0003] GUVs are mainly prepared by traditional methods such as hydration, electroformation, and phase transfer, which have disadvantages such as uneven size, difficult control, and low encapsulation efficiency of loaded substances. All of the above disadvantages can be overcome by using microfluidic technology to prepare lipid-based vesicles, giving GUVs obtained by microfluidic technology the advantages of monodispersity, adjustable size, high encapsulation rate, and uniform encapsulation. The microfluidic method prepares water-in-oil-in-water (W / O / W) double emulsions, phospholipids are dissolved in the intermediate oil phase, surfactants are added to the continuous phase to complete the dewetting process, and the organic layer is removed by the dewetting process to obtain giant liposomes. Double emulsions can easily incorporate hydrophilic and hydrophobic drugs into liposomes, and are also used to encapsulate proteins, nucleic acids, cells, and microparticles into liposomes.
[0004] However, the attachment of surfactants to the surface of liposomes not only changes the biophysical properties of the membrane, but also has an adverse effect on studies such as the assembly of proteins on the membrane. The liposomes ultimately formed using the double emulsion method will also have residual organic solvents, which may be highly toxic to biologically active ingredients, which is not conducive to research in bionic fields such as artificial cells, and may reduce the stability of the liposomes. Summary of the invention
[0005] In view of this, the present application provides a method for preparing giant liposomes without surfactant. The entire preparation process does not require the addition of surfactant, and the finished liposomes have good biocompatibility and can be applied to artificial cells and biological fields.
[0006] Specifically, the present application is implemented through the following scheme: A method for preparing giant liposomes without surfactant comprises the following steps: mixing phospholipids and squalene to form a first dispersed phase fluid, adding a continuous phase and a second dispersed phase fluid, and using the continuous phase as the outer phase, the first dispersed phase fluid as the middle phase, and the second dispersed phase fluid as the inner phase. The three are respectively injected into a microfluidic device, and the formed double emulsion is spontaneously dehumidified to obtain giant liposomes with an outer diameter of 30 to 150 μm.
[0007] In the above scheme, the lipid-containing first dispersed phase fluid (oil phase, LO) shears the second dispersed phase fluid (inner aqueous phase, IA) to form a single emulsion of oil-in-water (W / O), and the single emulsion is further sheared by the external continuous phase (external aqueous phase, OA) of a certain viscosity to form a double emulsion (W / O / W). The main component of the first dispersed phase fluid, squalene, is extracted from shark liver oil and has no biological toxicity. The amphiphilicity of phospholipids enables it to self-assemble at the two oil-water interfaces of the double emulsion to form a phospholipid molecular layer that stabilizes the oil-water interface, giving the structure a spontaneous dewetting property, and can continuously produce a monodisperse emulsion. The phospholipid bilayer formed during the dewetting process is the liposome; during the molding process, the size of the internal phase droplets determines the size of the liposome. In this case, the first dispersed phase fluid cooperates with the continuous phase and the second dispersed phase fluid and the molding process of the microfluidic device to achieve osmotic pressure balance in the molding process, stable liposome molding, uniform size, and adjustable size.
[0008] Further, as a preference: The continuous phase can be selected from a polyvinyl alcohol aqueous solution or a sucrose aqueous solution, but is not limited to the aqueous solutions of the above substances. The continuous phase meets a certain viscosity, and when the shearing effect is exerted, the single emulsion forms a double emulsion. More preferably, the polyvinyl alcohol aqueous solution is a mixture of polyvinyl alcohol and deionized water, and the mass ratio of polyvinyl alcohol to water is 0.01 to 0.3:1. Add polyvinyl alcohol to deionized water at normal pressure and room temperature, and stir evenly to form a continuous phase; the sucrose aqueous solution is a mixture of sucrose and deionized water, and the mass ratio of sucrose to deionized water is 0.05 to 0.1:1.
[0009] In the first dispersed phase fluid, the amount of phospholipids corresponding to each mL of squalene is 0.001-0.02 g. More preferably, the preparation method of the first dispersed phase fluid is: at normal pressure and room temperature, a chloroform solution of phospholipids is blown dry with nitrogen to form a phospholipid film, squalene is added, and the phospholipids are dissolved by ultrasound at 50°C to form the first dispersed phase fluid.
[0010] The second dispersed phase fluid can be selected from polyethylene glycol aqueous solution, polyvinyl alcohol and polyethylene glycol aqueous solution or glucose aqueous solution, but is not limited to the aqueous solutions of the above substances. More preferably, in the polyvinyl alcohol and polyethylene glycol aqueous solution, the mass ratios of polyvinyl alcohol, polyethylene glycol and deionized water are 0.01~0.1:1 and 0.01~0.3:1 respectively. The preparation method is: polyethylene glycol and polyvinyl alcohol are added to deionized water at normal pressure and room temperature, and stirred evenly to form a second dispersed phase. In the polyethylene glycol aqueous solution, the mixing mass ratio of polyethylene glycol to deionized water is 0.01~0.3:1. In the glucose aqueous solution, the mass ratio of glucose to deionized water is 0.01~0.1:1. The above solution maintains a balance with the continuous phase osmotic pressure, which can prevent the rupture of liposomes and effectively achieve the stability of liposomes.
[0011] In the microfluidic device, the flow rate Q of the first dispersed phase fluid is O The flow rate of the second dispersed phase fluid Q is 50~1500μL / h. W1 The continuous phase flow rate Q is 50~1000μL / h. W2 The flow rate is 1000-5000 μL / h. During the preparation process, the uniformity and adjustable size of the liposomes can be achieved with the aid of a microfluidic device.
[0012] The microfluidic device is a PDMS microfluidic device, with three liquid inlets, three corresponding syringes fixed thereto, and one liquid outlet.
[0013] The present invention has the following beneficial effects: First, the preparation method of the present invention is simple to operate, easy to control and adjust, and can continuously produce monodisperse, high encapsulation efficiency, surfactant-free, biomolecule-compatible giant liposome vesicles.
[0014] Second, the preparation method of the present invention can accurately control the components and content of the vesicle contents, and the method can be used for research in the fields of drug transport, release and artificial cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 is a schematic diagram of the structure of the microfluidic device in this application, Numbers in the figure: 1. Liquid inlet 1, 2. Liquid inlet 2, 3. Liquid inlet 3, 4. Liquid outlet; Figure 2 It is a camera picture of double emulsion dehumidification to form liposomes; Figure 3 It is a camera photo of the double emulsion dehumidification process; Figure 4 This is a fluorescence microscopy photograph of liposomes. DETAILED DESCRIPTION
[0016] The preparation method of the surfactant-free giant vesicles of the present invention is further described below by way of examples and in conjunction with the accompanying drawings, but the present invention is not limited to these examples.
[0017] The preparations involved in this embodiment are mainly as follows:
[0018] The molecular weight of polyvinyl alcohol is 13000-23000 and is purchased from Sigma-Aldrich Company.
[0019] Polyethylene glycol with a molecular weight of 6000 was purchased from Sigma-Aldrich.
[0020] Squalene was purchased from Sigma-Aldrich.
[0021] Phospholipids were purchased from Avanti.
[0022] The devices involved in this embodiment are mainly as follows:
[0023] The following embodiments can use various types of microfluidic devices with double emulsion generators, taking the PDMS microfluidic device as an example, combined with Figure 1 , which includes three liquid inlets: liquid inlet 1, liquid inlet 2, liquid inlet 3 and a liquid outlet 4. Each liquid inlet corresponds to an injection tube (not shown in the figure), which is fixed at the corresponding liquid inlet. The continuous phase is injected into the liquid inlet 1, the first dispersed phase fluid is injected into the liquid inlet 2, and the second dispersed phase fluid is injected into the liquid inlet 3; the liquid outlet is fixed with an output tube (not shown in the figure).
[0024] The following is a detailed explanation based on specific cases.
[0025] Example 1
[0026] The present embodiment provides a method for preparing giant liposomes without surfactant, and the steps are as follows: 1) Preparation of continuous phase: At normal pressure and room temperature, add 2 g of polyvinyl alcohol to 20 mL of deionized water, stir evenly to form a continuous phase fluid, and filter it for later use.
[0027] 2) Preparation of the first dispersed phase fluid: At normal pressure and room temperature, take 200 μL of chloroform solution of 50 mg / mL phospholipid into a glass bottle, blow dry the chloroform with nitrogen to form a phospholipid membrane. Then add 2 mL of squalene and dissolve the phospholipids by ultrasonication at 50°C for 1 h to form the first dispersed phase fluid.
[0028] 3) Preparation of the second dispersed phase fluid: Add 0.4 g polyvinyl alcohol and 1.6 g polyethylene glycol to 20 mL deionized water at normal pressure and room temperature, stir evenly to form the second dispersed phase fluid, and filter for later use.
[0029] 4) The second dispersed phase fluid prepared in step 3) is used as the inner phase (IA), the first dispersed phase fluid prepared in step 2) is used as the intermediate phase (LO), and the continuous phase prepared in step 1) is used as the outer phase (OA) and injected into different liquid inlets of the two-stage droplet generator of the microfluidic device through a syringe connected to a syringe pump to form water-in-oil-in-water double emulsion droplets. The inner phase flow rate Q W1 is 120 μL / h, and the intermediate phase flow rate Q O is 200 μL / h, and the external phase flow rate Q W2 2500μL / h.
[0030] 5) The sample is placed at the liquid outlet of the microfluidic device in step 4), where the double emulsion will spontaneously undergo a dewetting process (see Figure 3 ), forming giant liposome vesicles, see Figure 2 .
[0031] from Figure 2 It can be seen that the liposomes obtained in this example have clear outlines and their diameters are basically maintained above 40 μm.
[0032] Example 2
[0033] The configuration of this embodiment is the same as that of embodiment 1, except that: In step 2), 2 μg of rhodamine fluorescently labeled phospholipids are also added to the first dispersed phase fluid.
[0034] In step 3), 0.02 mg of calcein was also added to the second dispersed phase fluid.
[0035] The liposome solution was dropped onto the coverslip and observed using a fluorescence microscope after being excited by lasers at wavelengths of 488 nm and 561 nm. Figure 4 As shown, a clear red ring appears in the field of view, indicating that the outer layer of the vesicle is a phospholipid membrane, and the interior continues to emit green fluorescence, indicating that the vesicle is intact and the contents have not leaked.
[0036] Example 3
[0037] The present embodiment provides a method for preparing giant liposomes without surfactant, and the steps are as follows: 1) Preparation of continuous phase: At normal pressure and room temperature, add 2 g of polyvinyl alcohol to 20 mL of deionized water, stir evenly to form a continuous phase fluid, and filter it for later use.
[0038] 2) Preparation of the first dispersed phase fluid: At normal pressure and room temperature, take 200 μL of chloroform solution of 50 mg / mL phospholipid into a glass bottle, blow dry the chloroform with nitrogen to form a phospholipid membrane. Then add 2 mL of squalene and dissolve the phospholipids by ultrasonication at 50°C for 1 h to form the first dispersed phase fluid.
[0039] 3) Preparation of the second dispersed phase fluid: Add 0.6 g of polyvinyl alcohol and 1.4 g of polyethylene glycol to 20 mL of deionized water at normal pressure and room temperature, stir evenly to form the second dispersed phase fluid, and filter for later use.
[0040] 4) The second dispersed phase fluid prepared in step 3) is used as the inner phase (IA), the first dispersed phase fluid prepared in step 2) is used as the intermediate phase (LO), and the continuous phase prepared in step 1) is used as the outer phase (OA) and injected into different liquid inlets of the two-stage droplet generator of the microfluidic device through a syringe connected to a syringe pump to form water-in-oil-in-water double emulsion droplets. The inner phase flow rate Q W1 is 100 μL / h, and the intermediate phase flow rate Q O The external phase flow rate Q is 120 μL / h. W2 It is 2300μL / h.
[0041] 5) The sample is collected at the liquid outlet of the microfluidic device in step 4), wherein the double emulsion will spontaneously undergo a dewetting process to form giant liposomes, and the giant liposomes have a uniform diameter.
[0042] The different compositions of the continuous phase, the first dispersed phase, and the second dispersed phase will affect the fluid viscosity and osmotic pressure, and the viscosity affects the shear of the fluid in the microfluidic device. To form the inner and outer phases (the second dispersed phase and the continuous phase) of the liposome, the osmotic pressure must be balanced. By comparing Example 1 and Example 3, it can be seen that when the fluid composition changes, the flow rate also changes accordingly. The two complement each other to achieve the formation of liposomes with stable structure in this case.
[0043] Example 4
[0044] The present embodiment provides a method for preparing giant liposomes without surfactant, and the steps are as follows: 1) Preparation of continuous phase: At normal pressure and room temperature, add 2 g of polyvinyl alcohol to 20 mL of deionized water, stir evenly to form a continuous phase fluid, and filter it for later use.
[0045] 2) Preparation of the first dispersed phase fluid: At normal pressure and room temperature, take 200 μL of chloroform solution of 50 mg / mL phospholipid into a glass bottle, blow dry the chloroform with nitrogen to form a phospholipid membrane. Then add 2 mL of squalene and dissolve the phospholipids by ultrasonication at 50°C for 1 h to form the first dispersed phase fluid.
[0046] 3) Preparation of the second dispersed phase fluid: Add 1.4 g of sucrose to 20 mL of deionized water at normal pressure and room temperature, stir evenly to form the second dispersed phase fluid, and filter for later use.
[0047] 4) The second dispersed phase fluid prepared in step 3) is used as the inner phase (IA), the first dispersed phase fluid prepared in step 2) is used as the intermediate phase (LO), and the continuous phase prepared in step 1) is used as the outer phase (OA) and injected into different liquid inlets of the two-stage droplet generator of the microfluidic device through a syringe connected to a syringe pump to form water-in-oil-in-water double emulsion droplets. The inner phase flow rate Q W1 is 200 μL / h, and the intermediate phase flow rate Q O is 200 μL / h, and the external phase flow rate Q W2 It is 4200μL / h.
[0048] 5) The sample is collected at the liquid outlet of the microfluidic device in step 4), wherein the double emulsion will spontaneously undergo a dewetting process to form giant vesicles, and the diameter of the giant vesicles is uniform.
[0049] By comparing Example 1 with Example 4, it can be seen that when the first dispersed phase fluid provided in this case is used, when sucrose is used to replace polyvinyl alcohol and polyethylene glycol to form the second dispersed phase fluid, the same liposomes can be obtained at a higher flow rate.
[0050] The above description of the embodiments is to facilitate the understanding and use of the present invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments. Improvements and modifications made by those skilled in the art based on the principles of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A method for preparing giant liposomes without surfactant, characterized in that: Phospholipids are dissolved in squalene to form a first dispersed phase fluid, the content of phospholipids in each mL of squalene is 0.001-0.02 g, and a continuous phase and a second dispersed phase fluid are prepared, and the continuous phase is used as the outer phase, the first dispersed phase fluid is used as the middle phase, and the second dispersed phase fluid is used as the inner phase. The three are respectively injected into a microfluidic device, and the formed double emulsion is spontaneously dehumidified to obtain giant liposomes with an outer diameter of 30-150 μm.
2. The method for preparing a surfactant-free giant vesicle according to claim 1, characterized in that: The amount of phospholipids in each mL of squalene is 0.001~0.02g.
3. The method for preparing giant vesicles without surfactant according to claim 1, characterized in that: The first dispersed phase fluid preparation method is: at normal pressure and room temperature, the chloroform solution of phospholipids is blown dry with nitrogen to form a phospholipid film, squalene is added, and the phospholipids are ultrasonically dissolved to form the first dispersed phase fluid.
4. The method for preparing a surfactant-free giant liposome according to claim 1, characterized in that: The continuous phase is a polyvinyl alcohol aqueous solution or a sucrose aqueous solution.
5. The method for preparing a surfactant-free giant liposome according to claim 4, characterized in that: The polyvinyl alcohol aqueous solution is formed by dissolving polyvinyl alcohol in deionized water, and the mass ratio of polyvinyl alcohol to water is 0.01-0.3:1; the sucrose aqueous solution is formed by mixing sucrose and deionized water, and the mass ratio of sucrose to deionized water is 0.05-0.1:
1.
6. The method for preparing a surfactant-free giant vesicle according to claim 1, characterized in that: The second dispersed phase fluid is a polyethylene glycol aqueous solution, a polyvinyl alcohol and polyethylene glycol aqueous solution, or a glucose aqueous solution.
7. The method for preparing a surfactant-free giant vesicle according to claim 6, characterized in that: The aqueous solution of polyvinyl alcohol and polyethylene glycol is prepared by mixing polyvinyl alcohol, polyethylene glycol and deionized water, wherein the mass ratio of polyvinyl alcohol to deionized water is 0.01-0.1:1, and the mass ratio of polyethylene glycol to deionized water is 0.01-0.3:1; in the aqueous solution of polyethylene glycol, the mass ratio of polyethylene glycol to deionized water is 0.01-0.3:1; in the aqueous solution of glucose, the mass ratio of glucose to deionized water is 0.01-0.1:
1.
8. The method for preparing giant vesicles without surfactant according to claim 1, characterized in that: In the microfluidic device, the flow rate Q of the first dispersed phase fluid is O The flow rate of the second dispersed phase fluid Q is 50~1500μL / h. W1 The continuous phase flow rate Q is 50~1000μL / h. W2 1000~5000μL / h.
9. The method for preparing a surfactant-free giant vesicle according to claim 1, characterized in that: The microfluidic device is a PDMS microfluidic device, with three liquid inlets, three corresponding syringes fixed thereto, and one liquid outlet.
10. The method for preparing giant vesicles without surfactant according to any one of claims 1 to 9, characterized in that: The lipid-containing first dispersed phase fluid shears the second dispersed phase fluid to form a single water-in-oil emulsion, and the single emulsion is further sheared by the external continuous phase to form a double emulsion, which spontaneously dewets to form liposomes.
